Conventional open repair of a descending thoracic aortic aneurysm (TAA) remains a major invasive surgical procedure with significant inherent risk. These operations require thoracotomy, aortic clamping, partial aortic bypass to support the circulation, and considerable blood loss with associated transfusions. The surgical mortality rate may approach 12% even when performed by experienced surgeons in patients with good cardiac reserve and who are deemed excellent surgical candidates.
Conventional open repair of a descending thoracic aortic aneurysm (TAA) remains a major invasive surgical procedure with significant inherent risk. These operations require thoracotomy, aortic clamping, partial aortic bypass to support the circulation, and considerable blood loss with associated transfusions. The surgical mortality rate may approach 12% even when performed by experienced surgeons in patients with good cardiac reserve and who are deemed excellent surgical candidates. 1 Perioperative morbidity in this referenced cohort included spinal cord ischemia in 14%, respiratory failure in 20%, and renal insufficiency in 13% of patients undergoing open repair. These results have been achieved in centers of excellence using an experienced multidisciplinary team both intraoperatively as well as postoperatively, and may not be widely reproducible.
Physicians have embraced thoracic endograft technology with greater zeal than after United States Food and Drug Administration (FDA) approval of the first endovascular devices to treat abdominal aortic aneurysms. The Medtronic Vascular Talent Thoracic Stent Graft System (Medtronic Vascular, Santa Rosa, Calif) is a minimally invasive endovascular device that offers an alternative treatment for patients with TAA. This report summarizes the pivotal 30-day and 12-month results of the Evaluation of the Medtronic Vascular Talent Thoracic Stent Graft System for the Treatment of Thoracic Aortic Aneurysms (VALOR) trial, a study designed to evaluate the Talent Thoracic Stent Graft System in patients with TAAs. These endovascular results are compared with retrospective open surgical data from three centers of excellence: The Cleveland Clinic Foundation (Cleveland, Ohio), Massachusetts General Hospital (Boston, Mass), and The Hospital of the University of Pennsylvania (Philadelphia, Pa).
METHODS

Enrollment.
The VALOR trial was a prospective, nonrandomized, multicenter clinical study conducted in the United States to evaluate the safety and efficacy of the Medtronic Vascular Talent Thoracic Stent Graft in the treatment of thoracic aortic diseases. Enrollment occurred from December 2003 to June 2005 at 38 institutions across the United States (Appendix 1, online only). This report focuses on the pivotal test group population, which included patients diagnosed with TAAs. These patients were considered candidates for open surgical repair and were low to moderate risk (0, 1, and 2) per the modified Society for Vascular Surgery and the American Association for Vascular Surgery criteria (Appendix 2, online only). 2 The anatomic and medical inclusion and exclusion criteria are presented in Table I .
Surgical candidates with a fusiform thoracic aortic aneurysm Ն5 cm or Ն2 times the diameter of the nonaneurysmal aorta, as well as focal saccular thoracic aneurysms (penetrating atherosclerotic ulcers), were considered for inclusion. The aneurysm had to be at least 20 mm distal to the left common carotid and 20 mm proximal to the celiac artery, have a proximal and distal nonaneurysmal aortic neck diameter of between 18 and 42 mm, and proximal and distal nonaneurysmal aortic neck lengths of at least 20 mm. A notable exclusion criterion was previous surgical or endovascular treatment of an infrarenal aortic aneurysm.
Device description and deployment. The Talent Thoracic Stent Graft System consists of a preloaded stent graft and the CoilTrac delivery system (Medtronic). The implanted endoprosthetic portion of the Talent system is composed of a polyester graft fabric sewn to a self-expanding nickel-titanium (chemically polished nitinol) wire frame (Fig 1) . Catalog and custom stent graft configurations were made available for this trial (Appendix 3, online only). Stent graft oversizing of 2 to 4 mm relative to the native aortic diameter (measured as adventitia to adventitia) was recommended to provide the necessary outward radial force, maintaining stent graft apposition against the aortic wall. Preoperative diameter and length measurements were obtained from detailed computed tomography angiography (CTA) or magnetic resonance angiography (MRA). The overall design concept is modular, such that additional main sections as well as proximal and distal extensions are introduced separately and mated in vivo as needed to complete the exclusion of the TAA. The loaded delivery system is inserted in the femoral or iliac artery, tracks through the vasculature, and delivers the stent graft at the target site. Deployment of the proximal stent graft occurs as the outer sheath is withdrawn, initially exposing the proximal bare spring and first covered stent graft. A minimum overlap of 30 mm was required for multiple stent grafts, and the Reliant balloon catheter (Medtronic) could be used at the discretion of the physician to model the stent graft against the aortic wall. Adjunctive surgical techniques, including iliac artery conduits, spinal drains, and left subclavian artery (LSA) revascularization were left to the discretion of the investigator.
The study protocol was approved by the FDA and site institutional review boards. Patients signed an informed consent before participation in the investigational study.
Follow-up protocol. Standard follow-up evaluations were performed at 1, 6, and 12 months, and annually thereafter. Follow-up visits included a CT scan, chest radiograph, and physical examination. All clinical data were reported by the investigative center on case report forms and monitored by the sponsor. A Clinical Events Committee adjudicated major adverse events (MAEs) for device and procedure relatedness. Medical Metrx Solutions (M2S; West Lebanon, NH) served as the imaging core laboratory and provided critical and comprehensive data evaluation of all imaging studies, ensuring third-party assessment of graft effectiveness.
Endoleaks were defined according to the well-established type I to IV nomenclature. 3 In the event the core laboratory could not identify the source, the endoleak was classified as unknown. Migration was defined as Ͼ10 mm proximal or distal movement of the stent graft relative to fixed anatomic landmarks, and aneurysm expansion was defined as Ͼ5-mm increase in diameter from the 1-month to 12-month follow-up visit. An MAE was defined as death due to the procedure, any death Յ30 days of the procedure, respiratory complications, renal insufficiency or failure, cardiac events, neurologic events, aneurysm rupture, bowel ischemia, major bleeding, or vascular complications. A MAE that was identified as a serious adverse event by the clinical investigator was defined as serious MAE.
Aneurysm-related death was defined as any death Յ30 days from initial implantation or occurring as a consequence of an aneurysm rupture, a conversion to open repair, or any other secondary endovascular procedure relative to the aneurysm that was treated by the Talent Thoracic Stent Graft System as evidenced by CT scan, angiography, or direct observation at surgery or autopsy. Excluded were aneurysms in anatomic areas other than the targeted segment treated by the Talent Thoracic Stent Graft System. Aneurysm-related death after open repair included any death Յ30 days from the surgical procedure or any death caused by reintervention of the targeted aortic segment, or by complications related to the graft or the procedure.
Summary statistics presented for categoric variables are the number in each category and the percentage of known values that this number represents. For continuous variables, the mean and standard deviation are provided; P values were calculated using standard t tests. In some cases the median is provided as well. Kaplan-Meier curves were used to plot freedom from event over time. Tables II, III, and IV. Compared with the open surgery group, the subjects in the VALOR test group had similar age and gender distributions but had lower TAA size and were less likely to have a previous abdominal aortic aneurysm (AAA) or AAA repair. At the time of enrollment, 51 of 195 patients (26%) in the VALOR test group had aneurysm-related symptoms. The mean aneurysm length was 121.4 Ϯ 72.7 mm as measured by the core laboratory. These data were not available for the open surgery group.
RESULTS
Demographics
Procedure and hospital course. Vessel access and deployment of the study device at the intended site was successful in 194 (99.5%) of the 195 patients enrolled in the VALOR trial. One patient did not receive a study device because of access failure. Iliac conduits were required for arterial access in 21.1% of the patients. A mean number of 2.7 Ϯ 1.3 stent graft devices (range, 1-7) were implanted per patient. Approximately 25% of the patients had proximal main Talent Thoracic Stent Graft components implanted with diameters Ͻ26 mm (3 patients, 1.9%) or Ͼ40 mm (49 patients, 23.2%). The highest implantation zone (Fig 3) of the bare spring segment of the most proximally implanted device was zone 1 in 6.7% of patients, zone 2 in 26.8%, zone 3 in 35.6%, and zone 4 in 30.9%. The decision to revascularize the LSA was left to the implanting physician and was performed before the initial stent graft procedure in 10 of 194 patients (5.2%). 4 At the conclusion of the procedure, the 194 patients with a device implanted had patent stent grafts, with integrity maintained and freedom from twisting or kinking.
Clinical utility measures for the VALOR test group and the open surgery group are compared in Table V . The VALOR test group showed superiority in regards to subjects requiring blood transfusion, procedural blood loss, and length of procedure, as well as intensive care unit and overall hospital stay (P Ͻ .001).
Mortality. Four of 195 VALOR patients (2.1%) died Յ30 days after implantation. Causes of death for these patients included atheroembolic multisystem failure, stroke, periprocedural cardiac arrest, and complications from a myocardial infarction and perforated ulcer. Table VI describes the 30-day mortality rates for the VALOR test group compared with the open surgery group. The VALOR test group experienced a significantly lower rate of early mortality (2% vs 8%, P Ͻ .01). All-cause mortality at 12 months is presented in Table VII (16.1% vs 20.6%, P ϭ NS). Freedom from all-cause mortality is presented for both groups in Fig 4. Predictors of all-cause mortality at 12 months in the VALOR patients included prior stroke, with an odds ratio of 4.45 (P ϭ .019), chronic obstructive lung disease, with an odds ratio of 3.72 (P ϭ .008), and aneurysm length, with an odds ratio of 1.008 (P ϭ .017) for each additional millimeter.
Aneurysm-related mortality. Six of 192 patients (3.1%) in the VALOR test group died of an aneurysmrelated cause through 12 months of follow-up. Four patients died Յ30 days of the procedure. Two additional late deaths were adjudicated as aneurysm-related. In the open surgery group, 22 of 189 patients (11.6%) died of aneurysmrelated causes, and this difference was statistically significant at P Ͻ .002. Freedom from aneurysm-related death for both groups is presented in Fig 5. Conversion to surgery. One patient (0.5%) was converted to open surgical repair approximately 9 months after implantation for complications related to an apparent infection in the stented segment of the aorta. This patient was alive and fully evaluable at the 12-month postimplantation follow-up. Cerebrovascular accidents. Seven VALOR patients (3.6%) had a periprocedural stroke. Three patients had resolution of stroke-related disability at 12 months, death, or last follow-up. Logistic regression analysis was performed on the occurrence of stroke Յ30 days after the implantation procedure. Patients who had a history of AAA had an odds ratio of 7.1 for the occurrence of stroke (P ϭ .031), and implantation in zone 1 or zone 2 had an odds ratio of 15.2 for the occurrence of stroke (P ϭ .018). Denominator is 187 subjects with evaluable scans.
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Spinal ischemia. Postoperative paraplegia occurred Յ30 days in three of 195 VALOR patients (1.5%) and in a fourth patient at 32 days after implantation. All patients had placement of a lumbar drain at the time neurologic deficits were identified. None of these patients experienced recovery at the 1-year follow-up or by the time of death, and none of the patients with paraplegia had a previously treated AAA. Onset of paraparesis occurred Յ30 days in 14 VALOR patients (7.2%). The proportion of patients with unresolved paraparesis within 12 months or last known follow-up fell to 3.1% (6 of 192).
Logistic regression analysis was performed on the incidence of paraplegia or paraparesis within Յ30 days after the implantation procedure. The only covariate that was found to be a significant predictor was the use of a conduit for access, with an odds ratio of 4.13 (P ϭ .020).
Stent graft effectiveness. The core laboratory identified seven patients with a type I endoleak by the 30-day follow-up visit, as noted in Table IX . Most endoleaks were type II. Sixteen patients had 17 additional endovascular procedures, of which two procedures (1.0%) occurred in the 30-day period before discharge, and 15 procedures (8.1%) occurred at 31 to 365 days. Fourteen procedures were performed to resolve an endoleak. One patient had a procedure to resolve migration and to cover a pseudoaneurysm. One patient was treated for an aneurysmal expansion, and one patient was treated for a second aneurysm.
The core laboratory noted four stent graft migrations Յ12 months. Two migrations involved the proximal end of the graft moving distally, and two involved the distal end of the graft moving proximally. Only one patient required an additional intervention related to the migration. Aneurysm sac diameter was stable or shrinking in 91.4% of patients. In 11 patients (8.5%), the increase in maximal aneurysm diameter was Ͼ5 mm during this interval, and seven of these patients had endoleaks during follow-up. No study patient had loss of stent graft patency or instances of compression or collapse of the endograft Յ12 months.
In two patients the core laboratory confirmed stent fractures Յ12 months. Neither patient had adverse events related to these fractures.
DISCUSSION
The Talent Thoracic Stent Graft System was first implanted in Australia in January 1996 and received the Conformité Européene (CE) mark in April 1998. The original device has undergone two iterative changes leading up to this pivotal clinical trial, including a delivery system change and chemical polishing of the nitinol stent. Most importantly, the device has not been withdrawn from the commercial market for any reasons related to safety or effectiveness.
Data from worldwide experiences with the Talent Thoracic Stent Graft System have been reported in numerous articles, which describe the use of the device in the whole spectrum of thoracic aortic pathologies. Encouraging results in the elective treatment of thoracic aortic dissection were first reported in 1999, 5 followed by positive outcomes in the emergency treatment of aortic perforations due to ruptured TAA, type B aortic dissection, and traumatic injury. [6] [7] [8] The most comprehensive long-term experience with the device was described by Fattori et al. 9 In the United States, Criado et al 10 described their 8-year experience with the Talent Thoracic Stent Graft in 111 TAA patients and 75 type B aortic dissection patients, with an average follow-up of 40 months. The investigators found low mortality and morbidity and favorable midterm survival results. 10 After FDA approval of the TAG thoracic endo- Only one open surgical site could provide blood loss during procedure data. 11 there has been rapid dissemination of this technology.
The Talent Thoracic Stent Graft offers a wider range of diameter options than is currently available in the commercial United States market. Of the patients implanted with diameters Ͻ26 mm or Ͼ40 mm, 25% would not have been eligible for endovascular repair using commercially available devices owing to diameter sizing constraints.
In 33.5% of patients, the bare spring segment of the most proximally implanted device was in zones 1 or 2 of the aortic arch. The uncovered proximal stent allows for crossing of the great vessels and proximal fixation in the arch without occluding blood flow. There were no instances of asymmetric opening or asymmetric deployment of the proximal bare spring in this pivotal VALOR trial. In addition, there were no instances of erosion or perforation of the aortic wall by the uncovered proximal nitinol stent. Despite concerns about embolic stroke during endovascular maneuvers in the arch, the incidence of perioperative stroke in this series was remarkably low at 3.6%, and nearly half of these patients had resolution of stroke-related disability at 12 months, death, or last follow-up. Retrograde type A dissections have been reported with other thoracic endovascular devices as well as in association with open thoracic aortic procedures. In the VALOR trial, retrograde type A dissection developed in three of 195 enrolled patients (1.5%). In one of the patients, the core laboratory determined that the proximal neck length was in fact shorter than 10 mm, although this was not recognized by the site investigators. In another patient the proximal neck was also Ͻ20 mm, and the core laboratory recognized evidence of a chronic type B dissection, which was an anatomic exclusion for enrollment in the pivotal arm. In the third patient there was a proximal type I endoleak at the end of the procedure and overzealous ballooning, which inadvertently included the proximal bare spring, was the likely etiology. Further discussion of incidence and prevention of retrograde type A dissection during thoracic aortic endovascular procedures is beyond the scope of this article.
Although the delivery systems were mostly 24F and 25F in size, successful vessel access and deployment occurred in 99.5% of cases, with iliac artery conduits used in 21%. A subset analysis failed to reveal any correlation between French size, conduit use, or vascular complications at 30 days. The use of conduits in this study is comparable to that reported in other contemporary series, 12, 13 and experience has dictated that vascular access complications are frequent and may result in death. The need for conduits should be anticipated before arterial injury, particularly in elderly women with small, calcified, stenotic external iliac arteries. Because the longest Talent covered device available for this pivotal trial was 116 mm, 2.7 Ϯ 1.3 devices were placed per patient (range, 1-7 devices). Longer covered endografts (ie, 150 and 200 mm) would have resulted in fewer devices placed per patient. Despite this, the incidence of serious vascular complications in the VALOR pivotal trial (Table IV) compares favorably with the Gore TAG phase II multicenter trial in which longer endografts were introduced and deployed through an indwelling 22F or 24F sheath.
The 30-day paraplegia rate was low, and paraparesis was moderately high in the acute phase. Despite the 30-day paraparesis rate, this event carried a reasonably favorable prognosis, as demonstrated by the unresolved paraparesis rate of 3.1% at 12 months or last known follow-up. Strategies potentially mitigating paraplegia, such as spinal drains, were used at the discretion of the investigator when the perceived risk was significant. An interesting observation is that covariate analysis revealed conduit use was predictive of paraplegia or paraparesis. This is consistent with published reports defining retroperitoneal hemorrhage/hematoma, perioperative hypotension, and injury to the external iliac artery as contributing factors for spinal cord ischemia.
14 Future studies will need to identify effective perioperative spinal cord monitoring techniques and interventions, as well as postoperative treatment algorithms.
Although a mean number of 2.7 Ϯ 1.3 stent graft components (range, 1-7 devices) were implanted per patient, no junctional or type III endoleaks were detected at the 12-month follow-up. After deployment, there were no instances of loss of patency or stent graft collapse in this cohort of patients with 12-month follow-up. Continued follow-up of these patients will be necessary to document the long-term efficacy of the device; however, several singlecenter series using the Talent thoracic device have demonstrated durability. [15] [16] [17] The VALOR trial results support the use of the Talent Thoracic Stent Graft System as a safe and effective alternative to open surgical repair in patients with descending TAAs. These elderly patients, despite their significant comorbidities, had low mortality at 30 days and 12 months, as well as aneurysm-related mortality at 12 months, supporting a high rate of successful aneurysm treatment. Specifically, the device showed statistically superior performance with respect to acute procedural outcomes, 30-day MAEs, perioperative mortality, and 12-month aneurysm-related mortality compared with open surgery. These data are particularly meaningful given that the open surgery data were derived from high-volume centers with a reputation for surgical excellence and where the best surgical outcomes would be anticipated.
A review of the recent medical literature allows for comparison between the Talent Thoracic Stent Graft expe- rience vs the Gore TAG device based on Kaplan-Meier estimates. 18, 19 Similar rates in 30-day and 12-month allcause mortality and 12-month aneurysm-related mortality rates have been reported. When serious MAE rates are compared through 12 months by organ system, the VALOR test group and the subjects with a Gore TAG device have essentially the same profile of MAE rates. These comparisons demonstrate that despite fundamental differences in stent graft design, the Talent Thoracic Stent Graft as used in the VALOR test group performed in a substantially similar manner to the Gore TAG device when implanted in a similar group of study subjects.
CONCLUSIONS
The Talent 
